TLR2
Basics
Aliases:
This biomarker is also known as:- toll/interleukin-1 receptor-like protein 4,
- toll/interleukin 1 receptor-like 4,
- toll-like receptor 2,
- CD282 antigen,
- CD282,
- Toll/interleukin-1 receptor-like protein 4,
- TIL4,
Description…
TLR2, or toll-like receptor 2, is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLR2 is involved in the innate immune response to bacterial lipoproteins and other microbial cell wall components. TLR2 also plays a role in NF-kappa-B activation, cytokine secretion and the inflammatory response.
Attributes
| QA State: | Curated |
|---|---|
| Type: | Protein |
| Short Name: | |
| HGNC Name: | TLR2 |
Datasets
There are no datasets associated with this biomarker.
Organs
The following organs have data associated with this biomarker…
Breast
Attributes
| Phase: | Two |
|---|---|
| QA State: | Under Review |
Overview
TLR2 gene polymorphisms have been related to increased susceptibility to cancer development in various organs, including breast cancer.
Performance Comment
TLR2 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
Studies
This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.
Publications
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
Resources
External Resources for TLR2
Gene
Protein
Other
Biomuta
Mutation Statistics
| Gene Name: | TLR2 |
|---|---|
| UniProt Accession #: | O60603 |
| Mutated Sites Count: | 140 |
| Associated Pubmed ID Count | 20 |
| CancerDO Count | 24 |
| Affected Protein Function Sites Count: | 6 |
